G M Felker

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Inotropic therapy for heart failure: an evidence-based approach
    G M Felker
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 142:393-401. 2001
  2. ncbi A standardized definition of ischemic cardiomyopathy for use in clinical research
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 39:210-8. 2002
  3. ncbi Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    J Card Fail 16:230-8. 2010
  4. ncbi Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk
    Thomas P Cappola
    Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Circulation 105:1663-8. 2002
  5. ncbi Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
  6. ncbi Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation
    Brian Lima
    DUMC Box 3043, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 114:I27-32. 2006
  7. ncbi Natriuretic peptides in the diagnosis and management of heart failure
    G Michael Felker
    Outcomes Research Group, Duke Clinical Research Institute, and the Division of Cardiology and Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    CMAJ 175:611-7. 2006
  8. ncbi Troponin elevation in heart failure prevalence, mechanisms, and clinical implications
    Robb D Kociol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 56:1071-8. 2010
  9. ncbi Advances in the surgical treatment of heart failure
    Larry A Allen
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 23:249-53. 2008
  10. ncbi Risk stratification after hospitalization for decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Card Fail 10:460-6. 2004

Detail Information

Publications58

  1. ncbi Inotropic therapy for heart failure: an evidence-based approach
    G M Felker
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am Heart J 142:393-401. 2001
    ..Despite this fact, inotropes remain commonly used in the management of heart failure...
  2. ncbi A standardized definition of ischemic cardiomyopathy for use in clinical research
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 39:210-8. 2002
    ....
  3. ncbi Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    J Card Fail 16:230-8. 2010
    ..Our study sought to validate the prognostic value of RDW in heart failure and to explore the potential mechanisms underlying this association...
  4. ncbi Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk
    Thomas P Cappola
    Department of Medicine, Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Circulation 105:1663-8. 2002
    ..These findings suggest that secondary pulmonary hypertension may have different biological features in myocarditis and that patients with pulmonary hypertension and myocarditis should be targeted for aggressive medical therapy...
  5. ncbi Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Card Fail 12:684-8. 2006
    ..Although unadjusted clinical outcomes are better for African Americans presenting with ADHF, these differences diminished after adjustment for baseline characteristics...
  6. ncbi Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation
    Brian Lima
    DUMC Box 3043, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 114:I27-32. 2006
    ..Pre-transplant VAD and prolonged ischemic times are more important determinants of PGD. These data support continued aggressive utilization of marginal donor hearts in AL HT...
  7. ncbi Natriuretic peptides in the diagnosis and management of heart failure
    G Michael Felker
    Outcomes Research Group, Duke Clinical Research Institute, and the Division of Cardiology and Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    CMAJ 175:611-7. 2006
    ....
  8. ncbi Troponin elevation in heart failure prevalence, mechanisms, and clinical implications
    Robb D Kociol
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Am Coll Cardiol 56:1071-8. 2010
    ..Ultimately, this information might allow physicians to guide therapy, choose appropriate therapeutics, and improve HF outcomes...
  9. ncbi Advances in the surgical treatment of heart failure
    Larry A Allen
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Curr Opin Cardiol 23:249-53. 2008
    ..The purpose of this review is to discuss emerging surgical therapies in heart failure, in particular, mechanical cardiac support and mitral valve repair...
  10. ncbi Risk stratification after hospitalization for decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Card Fail 10:460-6. 2004
    ..Further research into the validity of this model in independent samples will potentially aid in the development of risk stratification strategies...
  11. ncbi The Valsalva maneuver: a bedside "biomarker" for heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 119:117-22. 2006
    ..Although often overlooked in clinical training and practice, the cardiovascular response to the Valsalva maneuver is a potentially useful, noninvasive means of evaluating filling pressures in patients with heart failure...
  12. ncbi Implantable left ventricular assist devices: new hope for patients with end-stage heart failure
    Carmelo A Milano
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    N C Med J 67:110-5. 2006
    ..Recently, the Food and Drug Administration approved implantable left ventricular assist devices (LVAD) as destination therapy (DT) for end-stage heart failure patients who are ineligible for cardiac transplantation...
  13. ncbi Anemia in patients with heart failure and preserved systolic function
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:457-62. 2006
    ..Although heart failure in the setting of preserved systolic function (PSF) is an important clinical problem, the relationship between anemia and outcomes in patients with PSF has not been carefully evaluated...
  14. ncbi Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure
    G Michael Felker
    Duke University School of Medicine, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 47:930-2. 2006
    ....
  15. ncbi The African-American heart failure trial: a new look at old drugs
    G Michael Felker
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Future Cardiol 1:311-3. 2005
    ..Future research will be required to assess whether benefits of this drug combination seen in AHeFT can be extended to the wider population of patients with advanced heart failure...
  16. ncbi N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 158:S37-44. 2009
    ..To examine the relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) and exercise capacity in a large contemporary cohort of patients with chronic heart failure...
  17. ncbi A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment
    Lynda A Szczech
    Renal Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Kidney Int 77:239-46. 2010
    ..These differential outcomes underscore the need for dedicated trials in these subpopulations...
  18. ncbi Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 50:40-7. 2007
    ..The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients...
  19. ncbi The pathophysiology of acute heart failure--is it all about fluid accumulation?
    Gad Cotter
    Duke University Medical Center, The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:9-18. 2008
    ....
  20. ncbi Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials
    G Michael Felker
    Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 158:422-30. 2009
    ..We performed a quantitative meta-analysis of available randomized controlled trials to determine whether titration of therapy based on natriuretic peptide measurements improves mortality in chronic heart failure...
  21. ncbi Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?
    Beth Davison Weatherley
    Momentum Research Inc, Durham, NC, USA
    Fundam Clin Pharmacol 23:633-9. 2009
    ..7-6.3). Early WHF is a common adverse event in patients admitted with AHF, and is associated with AHF severity and excessive 6-month mortality. WHF should be considered as a clinically important endpoint in AHF studies...
  22. ncbi The problem of decompensated heart failure: nomenclature, classification, and risk stratification
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 145:S18-25. 2003
    ..It also defines the current understanding of strategies for risk stratification in the setting of decompensated heart failure...
  23. ncbi Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure
    Benjamin H Trichon
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 91:538-43. 2003
    ..MR is common in patients with LV systolic dysfunction and heart failure. After adjusting for other clinical variables, the presence of MR independently predicted worsened survival...
  24. ncbi Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
    Wendy A Gattis
    Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
    Am J Cardiol 91:169-74. 2003
    ..These results also suggest that caution should be taken when withdrawing beta blockade in this population...
  25. ncbi Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study
    G Michael Felker
    Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Cardiol 41:997-1003. 2003
    ..The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF...
  26. ncbi Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:625-8. 2003
    ..Lower baseline hemoglobin is associated with risk of short-term adverse clinical outcomes in this population, even after controlling for other baseline differences...
  27. ncbi Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation
    Benjamin H Trichon
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 108:II103-10. 2003
    ....
  28. ncbi Diuretic strategies in patients with acute decompensated heart failure
    G Michael Felker
    Duke University School of Medicine and Duke Heart Center, Durham, NC, USA
    N Engl J Med 364:797-805. 2011
    ..Loop diuretics are an essential component of therapy for patients with acute decompensated heart failure, but there are few prospective data to guide their use...
  29. ncbi Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure
    Karen E Joynt
    Department of Medicine Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 93:783-5. 2004
    ..Baseline angiotensin-converting enzyme inhibitor plus beta-blocker use were associated with lower levels of CRP; no relation was found between CRP levels and aspirin or statin use...
  30. ncbi United States stock market performance and acute myocardial infarction rates in 2008-2009 (from the Duke Databank for Cardiovascular Disease)
    Mona Fiuzat
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 106:1545-9. 2010
    ..02). In conclusion, unadjusted and adjusted analyses of patients in the Duke Databank for Cardiovascular Disease indicated a significant correlation between a period of stock market decrease and increased AMI rates in our local cohort...
  31. ncbi Outcomes with an alternate list strategy for heart transplantation
    G Michael Felker
    Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
    J Heart Lung Transplant 24:1781-6. 2005
    ..The creation of an alternate list to match recipients with contraindications to traditional HT with sub-optimal donor organs has been implemented at some centers, but outcomes using this approach are uncertain...
  32. ncbi Anaemia and coronary artery disease severity in patients with heart failure
    G Michael Felker
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Eur J Heart Fail 8:54-7. 2006
    ..Exacerbation of myocardial ischemia in patients with heart failure, coronary disease, and anaemia patients has been suggested as a potential mechanism underlying this association...
  33. ncbi Anemia as a risk factor and therapeutic target in heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 44:959-66. 2004
    ..Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF...
  34. ncbi Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  35. ncbi Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    Eur J Heart Fail 11:170-7. 2009
    ..The prevalence and importance of liver function test (LFT) abnormalities in a large contemporary cohort of heart failure patients have not been systematically evaluated...
  36. ncbi Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acut
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO 80045, USA
    J Card Fail 14:777-84. 2008
    ..The natural evolution of signs and symptoms during acute heart failure (AHF) is poorly characterized...
  37. ncbi End points for clinical trials in acute heart failure syndromes
    Larry A Allen
    Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Am Coll Cardiol 53:2248-58. 2009
    ....
  38. ncbi Inflammatory biomarkers in heart failure
    John W Petersen
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
    Congest Heart Fail 12:324-8. 2006
    ..In this review, the authors analyze available data supporting the use of inflammatory markers both as biomarkers and as potential therapeutic targets...
  39. ncbi Inotropes in the management of acute heart failure
    John W Petersen
    Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 36:S106-11. 2008
    ..Whether newer inotropes with differing mechanisms of action will realize the potential clinical benefits of inotropic therapy without the risk remains a subject of ongoing investigation...
  40. ncbi Infectious complications in extended criteria heart transplantation
    Keshava Rajagopal
    Department of Surgery, Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Heart Lung Transplant 27:1217-21. 2008
    ..We hypothesized that other adverse outcomes, principally determined by recipient characteristics, occur at a higher rate in extended criteria recipients...
  41. ncbi Effect of nesiritide in patients with acute decompensated heart failure
    C M O'Connor
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    N Engl J Med 365:32-43. 2011
    ..Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent...
  42. ncbi Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need?
    Olga Milo-Cotter
    Momentum Research Inc, 3100 Tower Blvd, Suite 802, Durham, NC 27707, USA
    Cardiology 114:75-82. 2009
    ..Low oxygen saturation (SaO2) and systolic blood pressure (SBP) are signs of impending respiratory and circulatory failure that can be obtained quickly in patients with AHF...
  43. ncbi Impact of left ventricular assist device bridging on posttransplant outcomes
    Jay D Pal
    Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina 27705, USA
    Ann Thorac Surg 88:1457-61; discussion 1461. 2009
    ..However, referral for LVAD therapy may be limited secondary to reports of poor outcomes when mechanical circulatory support is required before transplantation...
  44. ncbi Relationship between anemia and health care costs in heart failure
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Card Fail 15:843-9. 2009
    ..Anemia is associated with higher morbidity and mortality in patients with heart failure (HF), but its implications for heath care costs are not well described...
  45. ncbi Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure
    Larry A Allen
    Duke Clinical Research Institute and Division of Cardiology, Durham, NC 27705, USA
    JAMA 299:2533-42. 2008
    ..Patients with chronic heart failure have impaired long-term survival, but their own expectations regarding prognosis have not been well studied...
  46. ncbi Mortality in primary and secondary myocarditis
    Todd C Pulerwitz
    Cardiology Division, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Am Heart J 147:746-50. 2004
    ..Lymphocytic myocarditis presents as a primary disorder or in association with a systemic disease. Whether primary and secondary myocarditis have the same prognosis is unknown...
  47. ncbi Recurrence of cardiac sarcoidosis in a heart transplant recipient
    Jonathan E E Yager
    Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    J Heart Lung Transplant 24:1988-90. 2005
    ..He subsequently underwent uncomplicated heart transplantation. Nineteen months later, a routine surveillance endomyocardial biopsy specimen demonstrated recurrence of sarcoidosis in the transplanted heart...
  48. ncbi Left ventricular assist devices as destination therapy for end-stage heart failure
    Jonathan E E Yager
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 148:252-3. 2004
  49. ncbi Rational use of inotropic therapy in heart failure
    G M Felker
    Division of Cardiology, Department of Medicine, Duke University Medical Center, DUMC Box 3356, Durham, NC 27710, USA
    Curr Cardiol Rep 3:108-13. 2001
    ..An understanding of the appropriate goals of therapy is important for both patients and physicians if rational decisions about the use of inotropes are to be made...
  50. ncbi A global ranking approach to end points in trials of mechanical circulatory support devices
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    J Card Fail 14:368-72. 2008
    ..The ideal composite end point for studies of MCSDs is uncertain...
  51. ncbi Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trial
    Dianne H Leloudis
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
    J Heart Lung Transplant 25:1164-6. 2006
    ..A better understanding of the factors affecting pain during EMBx could improve the comfort level of this procedure...
  52. ncbi Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia
    Olga Milo-Cotter
    Momentum Research, Inc, Durham, NC 27707, USA
    Eur J Heart Fail 10:196-200. 2008
    ..Although diabetes is a common co-morbidity in heart failure, no prior study has considered the impact of serum glucose on this relationship...
  53. ncbi Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?
    Olga Milo-Cotter
    Duke University Medical Center and the Duke Clinical Research Institute, Durham NC, 27515, USA
    Eur J Heart Fail 9:178-83. 2007
    ..Although blood pressure (BP) is elevated in patients with acute heart failure (AHF), first admission BP has not been meticulously recorded before treatment in previous studies...
  54. ncbi The impact of arrhythmias in acute heart failure
    Raymond L Benza
    University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Card Fail 10:279-84. 2004
    ..CONCLUSION: New arrhythmia during an exacerbation of heart failure identifies a high-risk group with higher intrahospital and 60-day morbidity and mortality...
  55. ncbi Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    Circulation 111:2454-60. 2005
    ..CONCLUSIONS: In patients hospitalized for worsening heart failure, admission serum sodium is an independent predictor of increased number of days hospitalized for cardiovascular causes and increased mortality within 60 days of discharge...
  56. ncbi Unraveling the pathophysiology of acute heart failure: an inflammatory proposal
    G Michael Felker
    Am Heart J 151:765-7. 2006
  57. ncbi A bridge for the 21st century in heart transplantation?
    G Michael Felker
    Am Heart J 145:198-9. 2003
  58. ncbi B-type natriuretic peptide - a biomarker for all seasons?
    Daniel B Mark
    N Engl J Med 350:718-20. 2004